Cure My Disease

Don't miss your cure!

 Log in / Sign up

Herbal granules aim to revive immune system in HIV patients

NCT ID NCT07698548

Not yet recruiting Disease control Sponsor: Beijing University of Chinese Medicine Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study tests whether adding Fuyang Jiedu Granules, a traditional Chinese herbal mixture, to standard antiretroviral therapy can improve immune function in people with HIV who have persistently low CD4 counts despite viral suppression. The trial includes 240 adults aged 18–60 who have been on HIV treatment for years but still have weak immune systems. Participants will receive either the herbal granules plus their usual HIV drugs or the drugs alone for 48 weeks, with follow-up for another 48 weeks. The main goals are to see if CD4 counts rise and if more people achieve a healthy immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Fuyang Jiedu Granules (herbal mixture including Polygonatum, Epimedium, deer antler, Codonopsis, Scutellaria baicalensis, Scutellaria barbata)
What this could lead to
If successful, this could offer a new add-on treatment to help people with HIV rebuild their immune system when standard therapy alone is not enough.
What could go wrong
This is a single trial with 240 participants, and the herbal granules are based on traditional Chinese medicine concepts that may not translate to clear benefits. The study is not blinded, which could bias results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACQUIRED IMMUNODEFICIENCY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACQUIRED IMMUNODEFICIENCY SYNDROME HIV -1 INFECTION IMMUNE RECONSTITUTION FAILURE IMMUNOLOGICAL NON-RESPONDER SPLEEN-KIDNEY YANG DEFICIENCY SYNDROME

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing University of Traditional Chinese Medicine

    Beijing, Beijing Municipality, 100029, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.